GeneHealth - Your precision medicine

Infantile Nephrotic Syndrome

Disease Details

Family Health Simplified

Buy Membership

Description: Infantile nephrotic syndrome is a rare kidney disorder in infants characterized by high levels of protein in the urine, low levels of protein in the blood, and swelling in various parts of the body.
Type: Infantile nephrotic syndrome can be of various types, including congenital nephrotic syndrome (most commonly Finnish type). The type of genetic transmission for congenital nephrotic syndrome, Finnish type, is autosomal recessive.
Signs And Symptoms: Infantile nephrotic syndrome is a kidney disorder that occurs in infants and is characterized by several signs and symptoms. These typically include:

- Severe proteinuria: Excessive loss of protein in the urine.
- Hypoalbuminemia: Low levels of albumin (a type of protein) in the blood.
- Edema: Swelling, particularly in the face, abdomen, and legs, due to fluid retention.
- Hyperlipidemia: High levels of lipids (fats) in the blood.
- Weight gain: This can occur as a result of fluid retention.

Other symptoms may include:
- Poor appetite
- Fatigue
- Diarrhea
- Frequent infections due to a weakened immune system.
Prognosis: The prognosis for infantile nephrotic syndrome can vary widely depending on the underlying cause and the response to treatment. This condition often has a poor prognosis and can lead to chronic kidney disease or end-stage renal disease if not managed effectively. Early detection and appropriate treatment are crucial in determining the long-term outcome for affected infants.
Onset: Infantile nephrotic syndrome typically manifests within the first three months of life.
Prevalence: The prevalence of infantile nephrotic syndrome is relatively rare, with estimated incidence rates varying from 1 to 3 per 100,000 children globally.
Epidemiology: Infantile nephrotic syndrome is a rare kidney disorder that typically presents within the first three months of life. It is characterized by massive proteinuria, hypoalbuminemia, and edema. The incidence is estimated to be around 1 to 3 per 100,000 live births. This condition can be caused by genetic mutations, most notably in genes such as NPHS1, NPHS2, and WT1, and other congenital abnormalities or infections can also be contributing factors.
Intractability: Infantile nephrotic syndrome can be challenging to manage and treat. It often requires intensive medical intervention, including medications such as corticosteroids, immunosuppressants, and sometimes dialysis. The disease's intractability varies depending on the underlying cause and response to treatment, but it is generally considered difficult to control completely and may lead to significant complications.
Disease Severity: Infantile nephrotic syndrome is a severe kidney disorder that typically presents in the first three months of life. It is characterized by significant protein loss in the urine, leading to symptoms such as severe swelling (edema), hypoalbuminemia (low blood albumin levels), and high levels of cholesterol in the blood (hyperlipidemia). The disease often progresses rapidly and can lead to kidney failure if not managed appropriately.
Pathophysiology: Infantile nephrotic syndrome is a kidney disorder in infants characterized by severe proteinuria, hypoalbuminemia, edema, and hyperlipidemia. Its pathophysiology involves the following aspects:

1. **Genetic Mutations**: Mutations in genes such as NPHS1 (nephrin), NPHS2 (podocin), WT1 (Wilms' tumor 1), and LAMB2 (laminin beta-2) are often implicated. These genetic abnormalities affect the proteins vital for the structure and function of the glomerular filtration barrier.

2. **Podocyte Dysfunction**: The genetic mutations disrupt podocyte integrity, leading to a compromised glomerular filtration barrier. This allows the abnormal leakage of proteins, primarily albumin, into the urine (proteinuria).

3. **Proteinuria**: The massive loss of protein in the urine reduces plasma oncotic pressure, contributing to fluid accumulation in extracellular spaces (edema).

4. **Hypoalbuminemia**: The loss of albumin in the urine causes low levels of albumin in the blood.

5. **Hyperlipidemia**: Due to hypoalbuminemia, the liver increases the synthesis of lipoproteins, leading to elevated blood lipid levels.

6. **Edema**: The decreased oncotic pressure results in fluid movement from the vascular compartment to the interstitial spaces, causing swelling.

Understanding these mechanisms can guide diagnostic and therapeutic approaches for managing infantile nephrotic syndrome.
Carrier Status: Regarding infantile nephrotic syndrome, being a carrier means that an individual has one copy of a mutated gene that can cause the syndrome but does not exhibit symptoms themselves. This condition can often be inherited in an autosomal recessive manner, which means both parents must be carriers for the child to be affected.
Mechanism: Infantile nephrotic syndrome (INS) is primarily a genetic disorder that affects the kidneys, leading to significant proteinuria, hypoalbuminemia, hyperlipidemia, and edema.

### Mechanism:
INS often results from mutations in genes that are crucial for the normal function and structure of the glomerular filtration barrier, which includes the podocytes, basement membrane, and endothelial cells. These mutations impair the kidney's ability to retain proteins, resulting in their leakage into the urine.

### Molecular Mechanisms:
1. **NPHS1 (Nephrin)**: Mutations in this gene are a common cause of congenital nephrotic syndrome of the Finnish type. Nephrin is an essential component of the slit diaphragm between podocyte foot processes, which is crucial for the selective permeability of the glomerular filter.

2. **NPHS2 (Podocin)**: This gene encodes podocin, a protein that interacts with nephrin and CD2-associated protein (CD2AP) to support the slit diaphragm structure. Mutations in NPHS2 lead to autosomal recessive steroid-resistant nephrotic syndrome.

3. **WT1 (Wilms Tumor 1)**: Mutations in WT1, a gene critical for the development and function of the kidneys and gonads, can also cause INS. WT1 mutations can disrupt the differentiation and function of podocytes.

4. **LAMB2 (Laminin Beta-2)**: Mutations in this gene affect the basement membrane's integrity. Laminin beta-2 is a key component of the glomerular basement membrane, and its dysfunction can lead to Pierson syndrome, a severe form of infantile nephrotic syndrome.

5. **PLCE1 (Phospholipase C Epsilon 1)**: This gene plays a role in podocyte signaling, and its mutations can cause a form of INS. PLCE1 is involved in the regulation of the actin cytoskeleton, essential for maintaining podocyte structure.

In summary, the molecular mechanisms underlying infantile nephrotic syndrome involve defects in the proteins that maintain the integrity and function of the glomerular filtration barrier. These disruptions lead to the loss of the barrier's selective permeability and result in significant protein loss in the urine.
Treatment: For infantile nephrotic syndrome, treatment options vary depending on the underlying cause but generally include the following:

1. **Medications**:
- Corticosteroids (though often less effective in infants)
- Immunosuppressive drugs
- ACE inhibitors or ARBs (to reduce proteinuria)
- Diuretics (to manage edema)
- Antibiotics (to treat or prevent infections)

2. **Nutritional Support**:
- High-protein, low-salt diet
- Vitamin and mineral supplements

3. **Management of Complications**:
- Vaccinations to prevent infections
- Blood pressure control
- Management of thromboembolic risk

In some cases, more aggressive treatments may be necessary, including:

4. **Dialysis**:
- In cases of severe kidney dysfunction

5. **Kidney Transplant**:
- For children progressing to end-stage renal disease

The specific treatment plan should be tailored to the individual patient's condition and response to initial therapies. Regular monitoring and follow-up with a pediatric nephrologist are crucial.
Compassionate Use Treatment: For Infantile Nephrotic Syndrome (INS), treatment approaches can be challenging due to the rare and severe nature of the condition. Here are some avenues explored under compassionate use and off-label or experimental treatments:

1. **Gene Therapy**: As INS is often caused by genetic mutations, therapies aimed at correcting the underlying genetic defects are under experimental investigation.

2. **Biologic Agents**: Certain monoclonal antibodies like rituximab, which are typically used in other autoimmune conditions, might be considered for off-label use to reduce proteinuria when standard treatments fail.

3. **Angiotensin-Converting Enzyme (ACE) Inhibitors & Angiotensin II Receptor Blockers (ARBs)**: These drugs, used primarily for hypertension and heart failure, are sometimes used off-label to reduce proteinuria in INS by decreasing intraglomerular pressure.

4. **Calcineurin Inhibitors**: Off-label use of medications such as cyclosporine or tacrolimus can be employed to manage severe cases, although their use is associated with significant side effects.

5. **Stem Cell Therapy**: This is a more experimental approach, aiming to replace aberrant cells with healthy ones or to modulate immune response, but it is still in the research phase.

6. **Investigational Pediatric Nephrology Trials**: Enrolling in clinical trials for novel therapies tailored to INS can be another option, providing access to cutting-edge treatments that are not widely available.

Always consult with a healthcare professional specializing in pediatric nephrology to determine the best treatment plan for an individual case.
Lifestyle Recommendations: For infantile nephrotic syndrome, lifestyle recommendations focus on managing symptoms and improving quality of life for the affected child:

1. **Dietary Adjustments**:
- **Low Salt Diet**: Reducing salt intake to help control swelling and high blood pressure.
- **Adequate Protein Intake**: Ensure proper protein consumption, but this should be guided by a healthcare professional to avoid overloading the kidneys.
- **Balanced Diet**: Incorporating fruits, vegetables, and whole grains to maintain overall health.

2. **Hydration**:
- Ensuring the child drinks adequate fluids, but fluid intake may need to be monitored and restricted depending on the level of kidney function and fluid retention.

3. **Medication Adherence**:
- Strictly follow the prescribed medications, which may include corticosteroids, diuretics, or immunosuppressants, as directed by the healthcare providers.

4. **Regular Monitoring**:
- Frequent medical check-ups to monitor kidney function, protein levels, and other vital parameters.
- Home monitoring of weight and blood pressure can help detect early signs of complications.

5. **Prevention of Infections**:
- Due to their compromised immune system, vaccinations (as recommended by a healthcare provider) and avoiding exposure to infections are crucial.
- Good hygiene practices to reduce the risk of infections.

6. **Physical Activity**:
- Encouraging gentle physical activities suitable for the child's condition to promote overall health and well-being.

7. **Emotional and Psychological Support**:
- Providing emotional support to the child and family. Consider counseling or support groups for coping with chronic illness.

Always consult with healthcare professionals for personalized advice and management plans.
Medication: For infantile nephrotic syndrome, the standard treatment often involves medications such as corticosteroids (e.g., prednisone). In cases where corticosteroids are ineffective or inappropriate, immunosuppressive drugs such as cyclophosphamide, cyclosporine, or tacrolimus may be used. Additionally, medications to manage symptoms and complications, such as diuretics for edema, antihypertensives for blood pressure control, and anticoagulants to prevent blood clots, may also be indicated. The treatment plan is typically tailored to the specific needs and responses of the individual child. Regular monitoring and adjustment of the treatment regimen are essential for managing the condition effectively.
Repurposable Drugs: Information on repurposable drugs specifically for infantile nephrotic syndrome is limited due to the rarity and complexity of the condition. Treatment traditionally focuses on controlling symptoms and managing complications. Common therapeutic agents include corticosteroids, immunosuppressants like cyclosporine and tacrolimus, and ACE inhibitors. Repurposing drugs for this syndrome generally involves evaluating these existing medications for new potential benefits beyond their original uses. Collaboration with healthcare professionals is essential for determining appropriate treatments based on the patient's specific needs and response to therapy.
Metabolites: Infantile nephrotic syndrome can result in abnormalities in various metabolites. Key changes often involve:

1. **Albumin:** Decreased levels due to significant protein loss in urine.
2. **Cholesterol:** Elevated levels due to liver compensation for protein loss.
3. **Electrolytes:** Imbalances, particularly low levels of sodium and potassium.
4. **Lipids:** Increased levels, including triglycerides, as part of the body's response to proteinuria.
5. **Creatinine:** May be elevated if kidney function is significantly impaired.

Since you asked about "nan," it generally stands for "nanomolar" concentration but is not relevant here for a specific condition like infantile nephrotic syndrome unless in a context of detailed metabolic profiling which is not typically standard in diagnosis.
Nutraceuticals: Nutraceuticals are not standard treatments for infantile nephrotic syndrome. This condition, typically characterized by proteinuria, hypoalbuminemia, and edema, is usually managed with medications like corticosteroids, immunosuppressive agents, or even dialysis or kidney transplantation in severe cases. Nutritional support, including adequate protein and caloric intake, is often part of the comprehensive management plan, but specific nutraceuticals are not a recognized treatment option. Always consult with a healthcare provider for appropriate management.
Peptides: Infantile nephrotic syndrome is a rare kidney disorder in infants that causes significant protein loss in the urine (proteinuria). Peptide-based therapies and nanotechnology are emerging fields in the treatment of this disease. Peptides can be designed to specifically target and modify proteins involved in the disease process, potentially reducing proteinuria and slowing disease progression. Nanotechnology might be utilized to improve drug delivery systems, ensuring targeted and efficient treatment with minimal side effects. Research in these areas is ongoing to develop more effective treatments for infantile nephrotic syndrome.